Inflammatory Bowel Diseases

Inflammatory Bowel Diseases (Inflamm. Bowel Dis.) is published by Oxford University Press on behalf of the Crohn's & Colitis Foundation. Founded in 1995, it concentrates on clinical and basic research in inflammatory bowel disease, appears monthly, and had a 2025 impact factor of 5.5.《炎症性肠病》（Inflammatory Bowel Diseases''''，缩写 Inflamm. Bowel Dis.''）是牛津大学出版社代表克罗恩病与结肠炎基金会出版的刊物，1995 年创刊。该刊以炎症性肠病的临床与基础研究为主，现为月刊，二〇二五年影响因子为 5.5。

Scope

The journal's editorial stance is that a paper must concern the whole course of inflammatory bowel disease: however fine the immunological work, it has to bear on the diagnosis, treatment or care of patients with the disease. Coverage runs from mechanism to clinical care and concentrates on:本刊的取稿立场是「围绕炎症性肠病的全程」：一篇论文不论免疫学工作多么精细，都要说明它与炎症性肠病患者的诊断、治疗或照护有关。收文覆盖从机制到临床照护的链条，重点包括：

• Pathogenesis: intestinal immunity and the mucosal barrier, microbiome-host interaction, genetic susceptibility and risk loci, and environmental and dietary factors.发病机制： 肠道免疫与黏膜屏障、微生物组与宿主互作、遗传易感性与风险位点、环境与饮食因素。

• Epidemiology: regional variation in incidence and prevalence, time-trend analysis, risk and protective factors, and burden of disease and health service use.流行病学： 发病率与患病率的地区差异、时间与趋势分析、危险因素与保护因素、疾病负担与卫生服务利用。

• Diagnosis and assessment: endoscopic and imaging diagnosis, histological and pathological assessment, non-invasive markers, and activity and severity scores.诊断与评估： 内镜与影像诊断、组织学与病理评估、非侵入性标志物、疾病活动度与严重程度评分。

• Treatment, medical and surgical: biologics and small molecules, immunomodulators and steroids, nutritional therapy, and timing and choice of surgery.治疗（药物与外科）： 生物制剂与小分子药物、免疫调节与激素治疗、营养治疗、手术时机与术式选择。

• Translation and basic science: animal models and organoids, immune cell and cytokine research, validation of drug targets and mechanisms, and omics and multi-omics integration.转化与基础科学： 动物模型与类器官、免疫细胞与细胞因子研究、药物靶点与机制验证、组学与多组学整合。

• Clinical care: chronic disease management and follow-up, quality of life and psychosocial issues, paediatric and adolescent patients, and special situations such as pregnancy and vaccination.临床照护： 慢性病管理与随访、生活质量与心理社会问题、儿童与青少年患者、妊娠与疫苗接种等特殊情形。

The journal is hybrid and the publisher publishes neither review speed nor acceptance rate. The opening article of the first issue was The Historical Basis of the Idiopathic Inflammatory Bowel Diseases by Joseph B. Kirsner, and the journal has been indexed in MEDLINE since volume 4, issue 1, in 1998.本刊为混合出版，出版方未公布审稿时效与录用比例；创刊号首篇为（Joseph B. Kirsner）的《特发性炎症性肠病的历史基础》，本刊自 1998 年第 4 卷第 1 期起被 MEDLINE 收录。^[1]

History

• Founding (1995): the journal was founded in 1995 as a quarterly of about 350 pages a year, with the aim of providing a forum for clinical and basic research in inflammatory bowel disease. The founding co-editors-in-chief were Robert Burakoff and Richard P. MacDermott.创刊（1995年）： 1995 年创刊，创刊时为季刊、每年约三百五十页，创刊主旨是为炎症性肠病的临床与基础研究提供论坛；首任共同主编为（Robert Burakoff）与（Richard P. MacDermott）。

• Frequency: the journal began as a quarterly and has appeared monthly, twelve issues a year, since 2005, with volume numbering growing rapidly as pagination and issue count increased.刊期沿革： 创刊时为季刊，自 2005 年起改为月刊，每年十二期，卷号随页数与期数的增加而快速增长。^[2]

• Publisher: the journal was published by Raven Press at founding and has been published since 2018 by Oxford University Press on behalf of the Crohn's & Colitis Foundation.出版方沿革： 本刊创刊时由（Raven Press）出版，自 2018 年起由牛津大学出版社代表克罗恩病与结肠炎基金会出版。

• Metrics and indexing: the 2025 impact factor is 5.5 and the 2025 CiteScore 9.2, both official figures from the publisher. The journal is indexed in the Science Citation Index Expanded, Scopus and MEDLINE.指标与收录： 2025 年影响因子 5.5、2025 年引用分数 9.2（出版方官方值）；本刊被科学引文索引扩展版、Scopus 与 MEDLINE 收录。^[3]

Editors

The present editor is Sonia Friedman with Subra Kugathasan as deputy editor. The publisher's promotional material and its main site disagree, and both records stand.本刊现任主编为（Sonia Friedman），副主编为（Subra Kugathasan）；出版方的推广资料与主站记载不一致，两种记载并存。^[3]

• Conflict over the editorship: the publisher's official media kit still lists Fabio Cominelli as editor-in-chief and Sonia Friedman as editor, with an impact factor of 4.5 and a CiteScore of 9.7, alongside the main site's account. The two records reflect an incomplete handover and both are given here without choosing between them.主编记载冲突： 出版方官方推广资料仍列（Fabio Cominelli）为主编、（Sonia Friedman）为编辑（影响因子 4.5、引用分数 9.7），与主站的记载并存，属新旧交接期未同步，本稿并列写明而不取其一。^[4]

• Founding editors: the founding co-editors-in-chief Robert Burakoff and Richard P. MacDermott led the journal together from 1995 until 2016, the only tenure fully documented in the official editorial.首任主编： 首任共同主编（Robert Burakoff）与（Richard P. MacDermott）自 1995 年起共同主持本刊，任期至 2016 年，是创刊后唯一在官方社论中被完整记载的一任。

• Role in the field: as the official journal of the Crohn's & Colitis Foundation, the journal has recorded the field's move from limited treatment options to the biologic era, and its real-world studies are often used to assess the long-term effects of drugs.学科角色： 作为克罗恩病与结肠炎基金会的官方刊物，本刊是炎症性肠病领域由治疗选择有限走向生物制剂时代的主要记录者，其真实世界研究常被用于评价药物的长期效果。